- Home
- ULS vs INCY Comparison
ULS vs INCY Comparison
Compare ULS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- INCY
- Stock Information
- Founded
- ULS 1894
- INCY 1991
- Country
- ULS United States
- INCY United States
- Employees
- ULS N/A
- INCY N/A
- Industry
- ULS
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ULS
- INCY Health Care
- Exchange
- ULS Nasdaq
- INCY Nasdaq
- Market Cap
- ULS 11.3B
- INCY 13.4B
- IPO Year
- ULS 2024
- INCY 1993
- Fundamental
- Price
- ULS $71.50
- INCY $65.06
- Analyst Decision
- ULS Buy
- INCY Hold
- Analyst Count
- ULS 7
- INCY 19
- Target Price
- ULS $69.43
- INCY $72.67
- AVG Volume (30 Days)
- ULS 896.7K
- INCY 1.8M
- Earning Date
- ULS 05-06-2025
- INCY 04-29-2025
- Dividend Yield
- ULS 0.73%
- INCY N/A
- EPS Growth
- ULS 28.34
- INCY N/A
- EPS
- ULS 1.67
- INCY 0.10
- Revenue
- ULS $2,905,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- ULS $6.76
- INCY $13.29
- Revenue Next Year
- ULS $6.04
- INCY $10.43
- P/E Ratio
- ULS $42.85
- INCY $592.09
- Revenue Growth
- ULS 6.84
- INCY 17.13
- 52 Week Low
- ULS $37.87
- INCY $53.56
- 52 Week High
- ULS $72.81
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ULS N/A
- INCY 60.01
- Support Level
- ULS N/A
- INCY $63.51
- Resistance Level
- ULS N/A
- INCY $66.26
- Average True Range (ATR)
- ULS 0.00
- INCY 1.60
- MACD
- ULS 0.00
- INCY 0.32
- Stochastic Oscillator
- ULS 0.00
- INCY 83.12
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.